IT leads a flat week as global technology optimism offsets domestic rate pressure

The week ended with a narrow split across the three tracked sectors. IT was supported by a global technology rebound, while NBFCs and insurers remained exposed to regulatory and funding-cost concerns. Pharma held a modest gain despite fresh USFDA observations at manufacturing facilities.

The common macro thread was a firmer rupee and a higher domestic bond yield. The rupee ended at Rs 95.38 per US dollar, gaining 0.3% on the week, which is a modest headwind for the rupee value of overseas revenue at IT and pharma companies but lowers the cost of imported inputs. The India 10-year government bond yield rose to 6.91%, increasing the relevance of funding costs for NBFCs and insurers.

Indian IT shares followed global technology stocks higher after Nvidia reported strong second-quarter results and offered an upbeat revenue outlook. Salesforce also raised its full-year guidance, according to market reports. TCS rose 4.09% on Friday, Infosys gained 3.34%, Tech Mahindra advanced 3.18% and HCLTech added 2.68%; Wipro rose 2.58% after expanding its partnership with Google Cloud around Gemini Enterprise and agentic artificial-intelligence solutions. TCS also secured a Rs 1,537 crore order from Tejas Networks for radio access network equipment for BSNL’s 4G rollout. These developments improved sentiment around technology spending, although they do not by themselves establish a recovery in US discretionary spending.

The rupee’s 0.3% weekly appreciation to Rs 95.38 per US dollar is a mild translation headwind for companies with substantial dollar revenue. The offset is that a stable currency reduces near-term volatility in reported margins. The more important operating question remains whether US clients move beyond artificial-intelligence infrastructure spending into broader discretionary technology and consulting budgets. The material does not identify a scheduled IT result or guidance update for the coming week. Infosys has scheduled non-deal-roadshow meetings in Mumbai on August 31 and September 1, followed by a virtual group call on September 2; management commentary on demand and deal conversion will therefore be the sector’s dated item to watch.

NBFC and insurance shares remained under pressure as the market weighed proposed RBI restrictions on revolving or Flexi credit products. Bajaj Finance was among the financial stocks that weakened during the week, while SBI Life was also reported among the notable losers at the start of the week. Against that regulatory overhang, Bajaj Finance raised Rs 5,000 crore through secured non-convertible debentures carrying an 8.15% annual coupon and maturing on August 27, 2036; LIC subscribed to the issue. Jio Financial Services reported that Jio Credit’s AUM rose to Rs 30,667 crore in the first quarter of FY27 from Rs 25,622 crore in the preceding quarter. The material does not provide weekly price changes for Jio Financial or SBI Life.

The India 10-year government bond yield ended at 6.91%, up about 6 basis points from the previous week’s close. Kotak Institutional Equities said a possible 50-basis-point repo-rate increase could lift NBFC funding costs by 5 to 15 basis points, putting pressure on net interest margins. Higher yields raise the cost of refinancing maturing NCDs and can weigh on insurers’ bond portfolios, although strong AUM growth can partly offset the pressure for lenders. No scheduled RBI policy decision, insurance-policy decision or company result for this sector was identified for August 31 to September 4. The RBI feedback window on the draft NBFC rules closed on August 28, so the next focus is any subsequent regulatory response rather than a dated event.

Pharma and healthcare shares absorbed a mixed regulatory flow. Cipla’s Pithampur formulations facility received seven observations in a Form 483 after a USFDA follow-up inspection conducted from August 17 to August 25. The company said it would address the findings; the nature of the observations was not disclosed. Cipla shares slipped after the disclosure. Aurobindo Pharma’s facility in Telangana received one USFDA observation, while Caplin Point Laboratories’ injectable and ophthalmic facility received 10 observations; Caplin shares fell 2% in the reported session. These developments kept manufacturing compliance at the centre of the sector’s risk assessment.

There were also positive approval-related developments. Jubilant Pharmova received USFDA approval for commercial batch manufacturing of the first product on a new fill-and-finish line at its Spokane facility. The material does not provide Jubilant’s weekly price change. The rupee gained 0.3% on the week to Rs 95.38 per US dollar. That can reduce the rupee value of US sales, but it also limits the cost of imported materials; the net effect depends on each company’s revenue and cost mix. US generic pricing remains a separate pressure point, with proposed phased US tariffs on generic-drug imports creating a longer-term uncertainty, although the available material does not identify a scheduled US pricing decision or pharma result for the coming week.

The coming week has no confirmed sector-wide earnings release, RBI policy decision or insurance-regulatory event in the available calendar. For IT, Infosys’s scheduled investor meetings on August 31 and September 1, and its virtual session on September 2, are the clearest dated events. For NBFCs, the market will continue to assess the RBI’s response to feedback on revolving-credit rules and the effect of the higher bond yield on funding costs. For pharma, further company disclosures on the cited USFDA observations would be relevant, but no such disclosure is scheduled in the material.

Across the three sectors, the next week’s risk balance therefore depends more on follow-through than on a single known catalyst: whether global technology optimism reaches discretionary IT demand, whether funding-cost concerns intensify for NBFCs and insurers, and whether US regulatory developments remain contained at pharma facilities. Brent crude settled at $89.31 a barrel after falling 5.1% on the week; the lower oil price supports India’s external balance and can indirectly help the rupee, but its direct relevance to these three sectors is limited compared with currency, regulation and bond yields.